Reactive neutrophilic
dermatoses in adult-onset immunodeficiency due to
interferon-γ
autoantibody (AOID) are usually associated with concomitant active
opportunistic infections. Data focusing on the treatment of these
dermatoses with non-immunosuppressive drugs are still lacking. The aim of this study was to assess the efficacy and safety of
acitretin treatment of reactive neutrophilic
dermatoses in AOID. We conducted a retrospective review of all patients with AOID who had reactive neutrophilic
dermatoses and had been treated with
acitretin from January 2008 to December 2018. In total, 23 patients had been diagnosed with AOID, with 27 episodes of reactive neutrophilic
dermatoses (20 episodes of
Sweet syndrome and seven episodes of generalized pustular eruption) and treated with
acitretin. The median effective dose of
acitretin was 10 mg/day. The mean initial response was 5.6 ± 2.3 days. The
rash had almost or completely cleared within 2 weeks in 70.4% of patients. One case had developed a reversible
acitretin-induced liver injury with hepatocellular pattern. The median total
duration of treatment was 3 months. In conclusion, this study demonstrates the potential role of
acitretin as one of the treatments of choice for reactive neutrophilic
dermatoses in AOID, attributable to its favorable response and good tolerability.